Published in Kidney Int on March 01, 2005
Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A (2005) 1.20
Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol (2008) 1.04
Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol (2009) 1.03
Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol (2011) 1.03
Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol (2010) 0.95
Pathways of apoptosis in human autosomal recessive and autosomal dominant polycystic kidney diseases. Pediatr Nephrol (2008) 0.85
Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. PLoS One (2013) 0.85
Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Mol Biol Rep (2012) 0.83
Polycystins and cellular Ca2+ signaling. Cell Mol Life Sci (2012) 0.78
Loss of PKD1 and loss of Bcl-2 elicit polycystic kidney disease through distinct mechanisms. Cell Death Differ (2005) 0.77
Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS One (2014) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Renal failure in cirrhosis. N Engl J Med (2009) 4.46
Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med (2013) 4.34
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol (2011) 3.53
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol (2005) 3.38
Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis (2004) 3.35
Diagnosis and treatment of acute tubular necrosis. Ann Intern Med (2002) 3.33
Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med (2007) 3.22
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int (2008) 2.92
Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol (2011) 2.90
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20
Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int (2010) 2.12
Mediators of inflammation in acute kidney injury. Mediators Inflamm (2010) 2.05
Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int (2005) 2.03
Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol (2009) 2.02
Psychosocial determinants of outcomes in knee replacement. Ann Rheum Dis (2011) 1.99
Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis (2002) 1.92
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther (2007) 1.88
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol (2006) 1.88
Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol (2012) 1.80
Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int (2005) 1.72
Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis (2008) 1.71
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc (2003) 1.64
Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 1.62
Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care (2009) 1.61
Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol (2007) 1.59
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Circadian and seasonal variations of ventricular tachyarrhythmias in patients with early repolarization syndrome and Brugada syndrome: analysis of patients with implantable cardioverter defibrillator. J Cardiovasc Electrophysiol (2012) 1.59
Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics (2008) 1.58
Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int (2004) 1.57
Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant (2007) 1.55
Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int (2012) 1.55
Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol (2007) 1.55
Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis (2005) 1.55
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol (2011) 1.54
Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol (2009) 1.50
Pressure-wire based assessment of microvascular resistance using calibrated upstream balloon obstruction: a predictor of myocardial viability. Catheter Cardiovasc Interv (2011) 1.49
Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol (2013) 1.48
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens (2006) 1.47
Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail (2008) 1.45
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.40
Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) (2003) 1.39
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol (2009) 1.36
Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol (2011) 1.35
Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med (2013) 1.34
Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol (2006) 1.32
Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol (2010) 1.30
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 1.28
Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol (2003) 1.28
Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol (2005) 1.27
Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol (2005) 1.26
AKI transition of care: a potential opportunity to detect and prevent CKD. Clin J Am Soc Nephrol (2013) 1.26
Acute renal failure and chronic kidney disease following liver transplantation. Hemodial Int (2007) 1.24
Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int (2008) 1.21
Anxiety in dementia: a critical review. Clin Psychol Rev (2008) 1.21
Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials. Clin J Am Soc Nephrol (2012) 1.20
Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A (2005) 1.20
Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol (2010) 1.20
Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol (2010) 1.19
Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med (2009) 1.19
Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol (2006) 1.18
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant (2009) 1.16
Left atrionodal connections in typical and atypical atrioventricular nodal reentrant tachycardias: activation sequence in the coronary sinus and results of radiofrequency catheter ablation. J Cardiovasc Electrophysiol (2006) 1.15
Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene. J Biol Chem (2003) 1.14
Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J Pharmacol Exp Ther (2007) 1.13
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
Peripheral CD4 T-cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation (2005) 1.12
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11
Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int (2002) 1.11